Blood Platelets Market Report 2026

The blood platelets market size has grown strongly in recent years. It will grow from $6.7 billion in 2025 to $7.17 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing surgical procedures, expansion of trauma care facilities, rising demand for platelet transfusions, growth in oncology treatments, improvements in blood collection infrastructure.

The blood platelets market size is expected to see strong growth in the next few years. It will grow to $9.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing prevalence of thrombocytopenia cases, rising demand from cancer treatment centers, expansion of advanced transfusion services, growing focus on transfusion safety, investments in next-generation platelet storage technologies. Major trends in the forecast period include increasing use of apheresis-derived platelets, rising adoption of pathogen-reduced platelet products, expansion of automated platelet collection systems, growing focus on platelet shelf-life extension, enhanced monitoring of platelet quality.

The rising prevalence of blood disorders is anticipated to drive the growth of the blood platelets market in the coming years. Blood disorders are conditions that impact the function, production, or components of blood, including red blood cells, white blood cells, platelets, or plasma, resulting in issues such as anemia, clotting disorders, or immune system deficiencies. The increasing prevalence of blood disorders is attributed to the aging population, as aging causes a decline in bone marrow function, making older adults more prone to conditions like anemia, thrombocytopenia, and clotting disorders. Blood platelets support blood disorder treatments by regulating blood clotting, making them vital for preventing excessive bleeding and promoting wound healing. For example, in October 2025, the World Federation of Hemophilia (WFH) Annual Global Survey (AGS) 2024 reported a 6% increase in the global identification of individuals with hemophilia, a 6% increase in those diagnosed with VWD, and a 9% increase in the detection of other inherited bleeding disorders. Consequently, the rising prevalence of blood disorders is fueling the growth of the blood platelets market.

Major companies operating in the blood platelet market are concentrating on developing innovative approaches, such as platelet pooling, to extend shelf life, improve availability, and assist blood centers in meeting the increasing demand for transfusions. Platelet pooling involves combining platelets from multiple whole blood donations to create a single platelet unit for transfusion, enhancing availability, efficiency, and resource utilization in blood supply management. For example, in February 2023, Terumo Blood and Cell Technologies, a US-based medical technology company, introduced the IMUGARD WB platelet pooling set after obtaining U.S. Food and Drug Administration (FDA) clearance. This innovation extends the shelf life of whole blood-derived platelets from five to seven days, increasing platelet availability for transfusion. It also offers an alternative source of platelet supply to address rising demand and donor shortages, supporting blood centers in improving inventory management and minimizing waste.

In December 2023, Sysmex Corporation, a Japan-based healthcare and diagnostics company, acquired additional shares in Megakaryon Corporation for an undisclosed amount. Through this acquisition, Sysmex aims to accelerate the commercialization of high-quality induced pluripotent stem (iPS) cell-derived platelets by utilizing Megakaryon’s technology, enhancing group synergies, and advancing regenerative medicine through automation and quality control innovations. Megakaryon Corporation is a Japan-based biotechnology company focused on producing human induced pluripotent stem (iPS) cell-derived platelets for safer and sustainable blood transfusions.

Major companies operating in the blood platelets market are Fresenius Kabi, Grifols S.A., CSL Behring, Octapharma AG, Terumo Corporation, Cerus Corporation, Macopharma, Biotest AG, Kedrion Biopharma, Bio Products Laboratory Ltd, LFB Group, Hemanext Inc, Cellphire Inc, American Red Cross, Sanquin, Canadian Blood Services, Australian Red Cross Lifeblood, New York Blood Center, Vitalant, HemaCare.

North America was the largest region in the blood platelets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood platelets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood platelets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the blood platelets market by increasing costs of imported apheresis machines, storage bags, pathogen reduction systems, and monitoring equipment. Hospitals and blood banks in North America and Europe are most affected due to reliance on imported collection and processing devices, while Asia-Pacific faces higher costs for platelet storage and transport technologies. These tariffs are raising operational expenses and affecting supply efficiency. However, they are also encouraging regional manufacturing of blood processing equipment and localized innovation in platelet preservation solutions.

The blood platelets market research report is one of a series of new reports that provides blood platelets market statistics, including blood platelets industry global market size, regional shares, competitors with a blood platelets market share, detailed blood platelets market segments, market trends and opportunities, and any further data you may need to thrive in the blood platelets industry. This blood platelets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood platelets, also called thrombocytes, are small, disc-shaped cell fragments in the blood that play a crucial role in clot formation and wound healing. They prevent excessive bleeding by adhering to damaged blood vessel walls, aggregating with other platelets, and releasing clotting factors to stabilize the clot and minimize blood loss. Produced in the bone marrow, they are vital for hemostasis and blood vessel repair.

The primary platelet types in the blood platelets market are whole blood-derived platelets and apheresis-derived platelets. Whole blood-derived platelets are obtained by separating platelets from a standard whole blood donation, often pooled from multiple donors for transfusion. Their applications include platelet function disorders, hemophilia, thrombocytopenia, and perioperative indications, while the end-users include hospitals, ambulatory surgical centers, blood banks, research laboratories, specialty clinics, cancer treatment centers, trauma centers, and others.

The blood platelets market consists of sales of platelet apheresis kits, platelet storage systems, platelet-derived growth factors (PDGFs), platelet function analyzers and platelet transfusion services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.